DNA Damage Response targeting Therapeutic Development Services
Introduction What We Can Offer Workflow Types of Services Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Creative Biolabs assists in identifying novel synthetic lethal interactions, validating promising drug targets, optimizing lead compounds for enhanced efficacy and safety, and generating robust preclinical efficacy data. Our expertise extends to developing predictive biomarkers for strategizing synergistic combination therapies, especially when integrating with immunotherapies. Our goal is to equip you with the data and insights necessary to confidently progress your therapeutic candidates towards clinical success.
Introduction of DNA Damage Response targeting Therapeutic Development Services
Genomic stability, vital for cell survival, is maintained by the DNA Damage Response (DDR). Cancer's inherent instability creates dependencies on specific DDR pathways, offering therapeutic vulnerabilities. DDR targeting drugs, like PARP inhibitors in BRCA-mutant cancers, show significant clinical benefit. Emerging research also highlights DDR's interaction with the immune system, suggesting powerful immunotherapy combinations.
Discover how we can help - Request a consultation.
Fig.1 Targeting overexpressed DNA repair proteins in cancer therapy.1
What We Can Offer
Customized Project Design
We begin with an in-depth consultation to thoroughly understand your unique research objectives, target indications, and specific hypotheses. This allows us to craft highly tailored experimental plans and strategies that precisely align with your project's goals, ensuring a personalized service experience from the outset.
Integrated Discovery to Preclinical Pipeline
We provide a seamless, end-to-end service, guiding your therapeutic candidate from initial target identification through comprehensive preclinical validation. This integrated pipeline encompasses high-throughput compound screening, meticulous lead optimization, and robust preclinical efficacy and safety assessments, all managed under one roof.
Diverse Preclinical Model Systems
We offer access to comprehensive in vitro models such as 2D and 3D cell culture models, as well as PDOs for personalized drug testing, and complex co-culture systems that mimic the tumor microenvironment. For in vivo studies, we utilize patient-derived xenograft (PDX) models, syngeneic mouse models that accurately reflect specific genetic backgrounds and DDR defects.
Workflow of DDR Pathway-Targeted Therapeutic Development Platform
Types of Our Services
Creative Biolabs offers comprehensive therapeutic development services focused on a broad spectrum of DDR pathways and their inhibitors.
PARP Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Our services encompass comprehensive screening for novel PARP inhibitors, rigorous evaluation of their efficacy in various HRD models, and meticulous assessment of their combination potential with conventional chemotherapy or other DDR inhibitors to maximize therapeutic impact.
Learn More →
ATR Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Our services are dedicated to identifying and developing potent and selective ATR inhibitors, meticulously evaluating their efficacy as monotherapies or in synergistic combination with DNA-damaging agents to profoundly enhance DNA damage and induce cancer cell death.
Learn More →
ATM Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Our services encompass the discovery and optimization of novel ATM inhibitors, precisely assessing their ability to sensitize cancer cells to DNA-damaging agents, and thoroughly exploring their therapeutic utility within specific genetic contexts or in combination strategies.
Learn More →
DNA-PK Inhibitor based DNA Damage Response targeting Therapeutic Development Service
We offer comprehensive services for the development and robust preclinical validation of DNA-PK inhibitors, with a strong focus on elucidating and optimizing their radiosensitizing and chemosensitizing capabilities across various tumor types.
Learn More →
CHK1/2 Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Our services include high-throughput screening for novel CHK1/2 inhibitors and meticulously evaluating their synergistic effects in various relevant cancer models, exploring their potential to overcome therapeutic resistance by preventing cell cycle arrest and promoting apoptosis.
Learn More →
WEE1 Inhibitor based DNA Damage Response targeting Therapeutic Development Service
We provide comprehensive services for the discovery and preclinical development of WEE1 inhibitors, rigorously assessing their efficacy as monotherapies or in powerful combination with chemotherapy or other DDR inhibitors.
Learn More →
PLK1 Inhibitor based DNA Damage Response targeting Therapeutic Development Service
Our services include the comprehensive development and testing of PLK1 inhibitors, meticulously evaluating their impact on mitotic progression and cell viability across diverse cancer types, and exploring their potential in combination therapies.
Learn More →
Highlights
Integrated & Accelerated Workflow
Our integrated solutions offer a comprehensive, single-provider approach that significantly accelerates timelines by minimizing hand-offs and reducing administrative burdens, allowing your project to advance rapidly and smoothly from concept to preclinical validation.
Proven Expertise & Track Record
Our extensive experience, built on rigorous scientific methodologies and adherence to industry best practices, translates directly into reliable results and informed decision-making for your pipeline.
Customized & Quality-Driven Approach
We pride ourselves on providing highly customized and flexible approaches, meticulously tailoring our services to align precisely with your specific scientific objectives and strategic goals.
Strategic Innovation in Immuno-Oncology
Our deep understanding of the DDR-immune system interplay positions us to develop next-generation combination therapies. We design innovative strategies to enhance anti-tumor immunity, activate pathways like STING, and overcome therapeutic resistance.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
-
Accelerated Discovery
Creative Biolabs' high-throughput screening platforms for DDR inhibitors facilitated the rapid identification of novel hits for our ATM-deficient cancer project. Their ability to quickly optimize chemical scaffolds and provide robust mechanism-of-action data drastically accelerated our discovery phase compared to traditional methods. - Prof. M**k Jones
-
Strategic Partnership
The deep expertise of Creative Biolabs' team in DDR-immunotherapy combinations was a game-changer for our program. Their guidance on STING pathway activation and T-cell modulation helped us design synergistic combination strategies that showed remarkable anti-tumor immune responses in preclinical models. - Dr. S**n Lee
FAQs
How does Creative Biolabs identify novel DDR targets?
We leverage advanced bioinformatics, multi-omics data analysis, and cutting-edge functional genomics platforms. This allows us to precisely pinpoint novel DDR targets and uncover synthetic lethal interactions that offer unique therapeutic vulnerabilities in cancer cells, thereby guiding the development of innovative therapeutic avenues.
How does Creative Biolabs address drug resistance?
Addressing drug resistance is a core focus of our services. We proactively tackle this challenge through in-depth mechanism-of-resistance studies, which involve identifying the molecular pathways and adaptations cancer cells employ to evade DDR-targeted therapies. Based on these insights, we develop and validate novel resistance biomarkers and design strategic combination therapies.
What makes Creative Biolabs' DDR-immunotherapy approach unique?
Our unique strength in DDR-immunotherapy lies in our deep understanding of how DNA damage response defects profoundly influence tumor immunogenicity and immune cell modulation. By enhancing neoantigen presentation, activating innate immune pathways like STING, and modulating immunosuppressive cells within the tumor microenvironment, we aim to significantly amplify anti-tumor immune responses.
Related Services
To further support your therapeutic development goals, Creative Biolabs offers a range of complementary services and specialized options.
Biomarker Discovery
This includes specialized biomarker panel screening services tailored for immuno-oncology, providing crucial insights into immune responses, inflammatory processes, and tumor microenvironments.
Learn More →
Biochemical Selectivity Services
This includes biochemical selectivity panel screening services for evaluating compound interaction with a wide range of specific biochemical targets, ensuring optimal potency while minimizing undesirable off-target effects.
Learn More →
Preclinical Services
A full suite of contract research organization services for preclinical in vitro and in vivo studies, encompassing toxicology assessments, ADME studies, and safety pharmacology evaluations.
Learn More →
How to Contact Us
Creative Biolabs' DNA damage response targeting therapeutic development services offer an integrated, expert-driven approach to accelerate your journey from scientific concept to clinical reality. Ready to advance your therapeutic development project? Contact us for more information and to discuss your project.
Reference
-
Qian, Jiekun, et al. "Advancing cancer therapy: new frontiers in targeting DNA damage response." Frontiers in Pharmacology 15 (2024): 1474337. Distributed under an Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3389/fphar.2024.1474337
For Research Use Only | Not For Clinical Use
